Sedation for Patients Undergoing Endoscopic Retrograde Cholangiopancreatography

Sponsor
Institute of Liver and Biliary Sciences, India (Other)
Overall Status
Completed
CT.gov ID
NCT04860167
Collaborator
(none)
90
1
3
14.1
6.4

Study Details

Study Description

Brief Summary

This study was performed to evaluate the role of BIS monitored sedation in reducing the dose of propofol and to know the effectiveness of pre-procedure administration of intravenous diclofenac sodium along with topical pharyngeal anesthesia in reducing the dose of propofol in patients undergoing endoscopic retrograde cholangiopancreatography.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

It was a single-center open-labeled Prospective Randomized study. After approval of the study by the institutional ethical committee & obtaining written informed consent, 90 patients scheduled for ERCP procedure were randomized by using the block randomization method into the following three groups, Group A (n=30)-The intravenous infusion of propofol was administered for the ERCP procedure based on clinical judgment and the patient's requirement.

Group B (n=30) - The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.

Group C (n=30) - Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure & topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.

In all three groups, after completing the standard pre-anesthesia checklist, patients were positioned in the semi prone-position and standard ASA monitors were attached (electrocardiogram, pulse oximetry, and non-invasive blood pressure, EtCO2). Also, the BIS monitor was attached in group B & group C. Baseline values were noted before the start of sedation. Supplemental oxygen was provided by nasal prongs @ 2/min. Patients in all groups were sedated with an initial bolus dose of fentanyl 1 mcg/kg & propofol 1-1.5 mg/kg intravenously. Sedation was maintained with propofol infusion at the rate of 80-100 mcg/kg/min. In group A, propofol sedation was further titrated based on clinical judgment and patient's requirement. Whereas in group B & group C, propofol sedation was further titrated to maintain a BIS value between 60-80. If the patient moves despite BIS 60-80, an additional bolus of 30 mg i.v. propofol was administered. In addition to these, i.v. fentanyl 25mcg was administered as a rescue analgesic.All pre-procedure drugs were administered in the preoperative room with standard ASA monitoring.

Hemodynamic parameters were monitored at 5-min intervals. The incidence and number of episodes of patient's movements, cough/gag reflex, and hiccups were noted. The incidence of desaturation (fall in oxygen saturation < 94 % with oxygen supplementation), hypotension (17) (defined as systolic blood pressure < 90 mm of Hg ), and bradycardia (defined as HR < 50 beats per minute) was also be noted. Standard anesthesia protocol was followed for the management of desaturation and hemodynamic instability. Desaturation was managed by chin lift & jaw thrust maneuver. The nasal airway was inserted if deemed necessary by the concerned anesthetist. Further, if desaturation persists & lack of respiratory effort is seen for more than 20 seconds, sedation was discontinued, and mask ventilation is initiated in the lateral position. Insertion of supraglottic airway devise or tracheal intubation (after turning the patient supine) performed as per anesthetist discretion and the patient will be excluded from the study. Hypotension managed with 6-12 mg of intravenous ephedrine or a fluid bolus of 500 cc of plasmalyte. Bradycardia is managed by 0.6 mg of intravenous atropine.

At the end of the procedure, propofol infusion was stopped and the total dose of propofol administered in mg/kg/hr was calculated. Thereafter, time to achieve eye-opening to verbal commands was calculated.

Post-procedure, patients were nursed in the left lateral position, and vitals (HR, NIBP, SpO2) was noted every 5 mins. Also, readiness to discharge is assessed by the noting post-anesthesia discharge score (PADS) every 15 mins. For patients having breakthrough pain, 1 gram iv paracetamol was administered in all the groups. The endpoint of complete recovery was a PADS score of 10. Also at the end of the procedure, the endoscopist was asked to grade ease of procedure based on 1=poor, 2=fair, 3=acceptable, 4=good, 5=excellent scale.

At the time of discharge, the patient's satisfaction for the ERCP procedure was grade on 1=unacceptable, 2=extremely uncomfortable, 3=slightly uncomfortable, 4=no discomfort scale.

Study Design

Study Type:
Interventional
Actual Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography: A Comparison Between Conventional Versus Bispectral Index Guided Approach and Effect of Diclofenac Sodium Along With Topical Pharyngeal Anaesthesia
Actual Study Start Date :
Sep 10, 2018
Actual Primary Completion Date :
Sep 26, 2019
Actual Study Completion Date :
Nov 14, 2019

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Group A

The intravenous infusion of propofol was administered for ERCP procedure based on clinical judgment and the patient's requirement.

Active Comparator: Group B

The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.

Drug: Propofol
Injection propofol was given to keep the BIS value 60-80 during the ERCP procedure
Other Names:
  • Neorof
  • Active Comparator: Group C

    Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure & topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.

    Drug: Diclofenac Sodium and Lignocaine 10 % spray
    Injection Diclofenac sodium was given in the preoperative area 30 minutes before the procedure and four squirts of 10% lignocaine were given 5 minutes prior to the start of the procedure
    Other Names:
  • Dynapar
  • Outcome Measures

    Primary Outcome Measures

    1. Total dose of propofol required in mg/kg/hr during ERCP procedure among different groups. [2 hours]

      Total dose of propofol required to complete the ERCP procedure was noted

    Secondary Outcome Measures

    1. Mean recovery time between different groups. [24 hours]

      Total time taken by the patient to reach a post-anesthesia discharge score of 10 was taken as the mean recovery time

    2. Time taken to achieve eye opening to verbal stimulus among different groups [24 hours]

      Total time taken by the patient to open eyes in response to the verbal commands after the propofol was stopped

    3. Incidence of hypotension, bradycardia, limb movements and gag reflex during the ERCP procedure [24 hours]

      Incidence of hypotension, bradycardia, limb movement and gag reflex was noted during the ERCP procedure

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age between 18-65 yrs

    2. ASA I & II

    Exclusion Criteria:
    1. Age < 18 yrs & > 65 yrs

    2. ASA III & IV patients

    3. Chronic Liver Disease

    4. Pregnant patients

    5. Patients with a history of (H/O) Drug abuse

    6. Patients refusing consent

    7. H/o Acute kidney injury

    8. H/o allergy to propofol / lidocaine/ NSAIDS

    9. Post liver transplant patients

    10. Patients with h/o egg allergy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Gaurav Sindwani New Delhi Delhi India 110060

    Sponsors and Collaborators

    • Institute of Liver and Biliary Sciences, India

    Investigators

    • Principal Investigator: gaurav sindwani, md, ilbs

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Gaurav Sindwani, Associate professor, Department of Anaesthesiology, Principal Investigator, Institute of Liver and Biliary Sciences, India
    ClinicalTrials.gov Identifier:
    NCT04860167
    Other Study ID Numbers:
    • ILBSIndia3
    First Posted:
    Apr 26, 2021
    Last Update Posted:
    Apr 26, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Gaurav Sindwani, Associate professor, Department of Anaesthesiology, Principal Investigator, Institute of Liver and Biliary Sciences, India
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 26, 2021